Metformin promotes apoptosis in hepatocellular carcinoma through the CEBPD-induced autophagy pathway

Oncotarget

Volumn 8, Issue 8, 2017, Pages 13832-13845

  Tsai, Hsin Hwa ^a   Lai, Hong Yue ^a   Chen, Yueh Chiu ^a   Li, Chien Feng ^b   Huang, Huei Sheng ^a   Liu, Hsiao Sheng ^a   Tsai, Yau Sheng ^a   Wang, Ju Ming ^a,c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Autophagy; CEBPD; HCC; Metformin

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN DELTA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; PROTEIN TYROSINE KINASE; RAPAMYCIN; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; CEBPD PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATG3 GENE; AUTOPHAGY; CONTROLLED STUDY; DRUG POTENTIATION; GENE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LC3B GENE; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PROTEIN DEGRADATION; ANIMAL; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECTS; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE SILENCING; LIVER TUMOR; METABOLISM; NONOBESE DIABETIC MOUSE; POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CCAAT-ENHANCER-BINDING PROTEIN-DELTA; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; HYPOGLYCEMIC AGENTS; LIVER NEOPLASMS; MALE; METFORMIN; MICE; MICE, INBRED NOD; MICE, SCID; MICROSCOPY, FLUORESCENCE; POLYMERASE CHAIN REACTION;

EID: 85013405278     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.14640     Document Type: Article

References (63)

1. Lozy F, Karantza V. Autophagy and cancer cell metabolism. Seminars in cell & developmental biology. 2012; 23:395-401
2. Cui J, Gong Z, Shen HM. The role of autophagy in liver cancer: molecular mechanisms and potential therapeutic targets. Biochimica et biophysica acta. 2013; 1836:15-26
3. Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, Stenmark H, Johansen T. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. The Journal of cell biology. 2005; 171:603-614
4. Lee YJ, Hah YJ, Kang YN, Kang KJ, Hwang JS, Chung WJ, Cho KB, Park KS, Kim ES, Seo HY, Kim MK, Park KG, Jang BK. The autophagy-related marker LC3 can predict prognosis in human hepatocellular carcinoma. PloS one. 2013; 8:e81540
5. Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nature reviews Endocrinology. 2014; 10:143-156
6. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver international. 2010; 30:750-758
7. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ (Clinical research ed). 2005; 330:1304-1305
8. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes care. 2009; 32:1620-1625
9. Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, Wu MS, Lin JH, Wu CY. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: populationbased and in vitro studies. Gut. 2013; 62:606-615
10. Saito T, Chiba T, Yuki K, Zen Y, Oshima M, Koide S, Motoyama T, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Tada M, Kanai F, et al. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PloS one. 2013; 8:e70010
11. Shi WY, Xiao D, Wang L, Dong LH, Yan ZX, Shen ZX, Chen SJ, Chen Y, Zhao WL. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell death & disease. 2012; 3:e275
12. Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A, Gounon P, Allegra M, Bertolotto C, Bereder JM, Tartare-Deckert S, Bahadoran P, Auberger P, et al. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell death & disease. 2011; 2:e199
13. Sivko GS, DeWille JW. CCAAT/Enhancer binding protein delta (c/EBPdelta) regulation and expression in human mammary epithelial cells: I. "Loss of function" alterations in the c/EBPdelta growth inhibitory pathway in breast cancer cell lines. Journal of cellular biochemistry. 2004; 93:830-843
14. Agrawal S, Hofmann WK, Tidow N, Ehrich M, van den Boom D, Koschmieder S, Berdel WE, Serve H, Muller-Tidow C. The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood. 2007; 109:3895-3905
15. Pan YC, Li CF, Ko CY, Pan MH, Chen PJ, Tseng JT, Wu WC, Chang WC, Huang AM, Sterneck E, Wang JM. CEBPD reverses RB/E2F1-mediated gene repression and participates in HMDB-induced apoptosis of cancer cells. Clinical cancer research. 2010; 16:5770-5780
16. Ko CY, Hsu HC, Shen MR, Chang WC, Wang JM. Epigenetic silencing of CCAAT/enhancer-binding protein delta activity by YY1/polycomb group/DNA methyltransferase complex. The Journal of biological chemistry. 2008; 283:30919-30932
17. Chuang CH, Wang WJ, Li CF, Ko CY, Chou YH, Chuu CP, Cheng TL, Wang JM. The combination of the prodrugs perforin-CEBPD and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer. Cell death & disease. 2014; 5:e1220
18. Yang X, Sun D, Tian Y, Ling S, Wang L. Metformin sensitizes hepatocellular carcinoma to arsenic trioxideinduced apoptosis by downregulating Bcl2 expression. Tumour biology. 2015; 36:2957-2964
19. Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science (New York, NY). 2004; 306:990-995
20. Gery S, Tanosaki S, Hofmann WK, Koppel A, Koeffler HP. C/EBPdelta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation. Oncogene. 2005; 24:1589-1597
21. Ikezoe T, Gery S, Yin D, O'Kelly J, Binderup L, Lemp N, Taguchi H, Koeffler HP. CCAAT/enhancer-binding protein delta: a molecular target of 1, 25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells. Cancer research. 2005; 65:4762-4768
22. Hsiao YW, Li CF, Chi JY, Tseng JT, Chang Y, Hsu LJ, Lee CH, Chang TH, Wang SM, Wang DD, Cheng HC, Wang JM. CCAAT/enhancer binding protein delta in macrophages contributes to immunosuppression and inhibits phagocytosis in nasopharyngeal carcinoma. Science signaling. 2013; 6:ra59
23. Sarkar TR, Sharan S, Wang J, Pawar SA, Cantwell CA, Johnson PF, Morrison DK, Wang JM, Sterneck E. Identification of a Src tyrosine kinase/SIAH2 E3 ubiquitin ligase pathway that regulates C/EBPdelta expression and contributes to transformation of breast tumor cells. Molecular and cellular biology. 2012; 32:320-332
24. Amaravadi RK. Autophagy-induced tumor dormancy in ovarian cancer. The Journal of clinical investigation. 2008; 118:3837-3840
25. Tsujimoto Y, Shimizu S. Another way to die: autophagic programmed cell death. Cell death and differentiation. 2005; 12:1528-1534
26. Law BK. Rapamycin: an anti-cancer immunosuppressant? Critical reviews in oncology/hematology. 2005; 56:47-60
27. Wu L, Feng Z, Cui S, Hou K, Tang L, Zhou J, Cai G, Xie Y, Hong Q, Fu B, Chen X. Rapamycin upregulates autophagy by inhibiting the mTOR-ULK1 pathway, resulting in reduced podocyte injury. PloS one. 2013; 8:e63799
28. Lonardo A, Ballestri S, Targher G, Loria P. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert review of gastroenterology & hepatology. 2014:1-22
29. Settembre C, De Cegli R, Mansueto G, Saha PK, Vetrini F, Visvikis O, Huynh T, Carissimo A, Palmer D, Klisch TJ, Wollenberg AC, Di Bernardo D, Chan L, et al. TFEB controls cellular lipid metabolism through a starvationinduced autoregulatory loop. Nature cell biology. 2013; 15:647-658
30. Polager S, Ofir M, Ginsberg D. E2F1 regulates autophagy and the transcription of autophagy genes. Oncogene. 2008; 27:4860-4864
31. Xu P, Das M, Reilly J, Davis RJ. JNK regulates FoxOdependent autophagy in neurons. Genes & development. 2011; 25:310-322
32. Milani M, Rzymski T, Mellor HR, Pike L, Bottini A, Generali D, Harris AL. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer research. 2009; 69:4415-4423
33. Ma D, Panda S, Lin JD. Temporal orchestration of circadian autophagy rhythm by C/EBPbeta. The EMBO journal. 2011; 30:4642-4651
34. Rouschop KM, van den Beucken T, Dubois L, Niessen H, Bussink J, Savelkouls K, Keulers T, Mujcic H, Landuyt W, Voncken JW, Lambin P, van der Kogel AJ, Koritzinsky M, et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. The Journal of clinical investigation. 2010; 120:127-141
35. Yeatman TJ. A renaissance for SRC. Nature reviews Cancer. 2004; 4:470-480
36. Zhang S, Yu D. Targeting Src family kinases in anticancer therapies: turning promise into triumph. Trends in pharmacological sciences. 2012; 33:122-128
37. Fung C, Chen X, Grandis JR, Duvvuri U. EGFR tyrosine kinase inhibition induces autophagy in cancer cells. Cancer biology & therapy. 2012; 13:1417-1424
38. Wu Z, Chang PC, Yang JC, Chu CY, Wang LY, Chen NT, Ma AH, Desai SJ, Lo SH, Evans CP, Lam KS, Kung HJ. Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors. Genes & cancer. 2010; 1:40-49
39. Kim J, Lee J, Kim C, Choi J, Kim A. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells. Tumour biology. 2016; 37:5811-5819
40. Balamurugan K, Sterneck E. The many faces of C/EBPdelta and their relevance for inflammation and cancer. International journal of biological sciences. 2013; 9:917-933
41. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nature reviews Cancer. 2013; 13:714-726
42. Qu H, Yang X. Metformin Inhibits Angiogenesis Induced by Interaction of Hepatocellular Carcinoma with Hepatic Stellate Cells. Cell biochemistry and biophysics. 2015; 71:931-936
43. Hsieh SC, Tsai JP, Yang SF, Tang MJ, Hsieh YH. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NFkappaB-dependent pathway that reduces uPA and MMP-9 expression. Amino acids. 2014; 46:2809-2822
44. Zhang ZY, Hong D, Nam SH, Kim JM, Paik YH, Joh JW, Kwon CH, Park JB, Choi GS, Jang KY, Park CK, Kim SJ. SIRT1 regulates oncogenesis via a mutant p53-dependent pathway in hepatocellular carcinoma. Journal of hepatology. 2015; 62:121-130
45. Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W, Ke J, Huang J, Yeung SC, Zhang H. Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell death & disease. 2014; 5:e1088
46. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer research. 2007; 67:10804-10812
47. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecologic oncology. 2008; 110:246-250
48. Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future oncology (London, England). 2010; 6:457-470
49. Carter HN, Hood DA. Contractile activity-induced mitochondrial biogenesis and mTORC1. American journal of physiology Cell physiology. 2012; 303:C540-547
50. Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, Gardenal R, Dal Mas M, Casarin P, Zanette G, Miranda C. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World journal of gastroenterology. 2009; 15:2506-2511
51. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. The American journal of gastroenterology. 2012; 107:46-52
52. Fujita K, Iwama H, Miyoshi H, Tani J, Oura K, Tadokoro T, Sakamoto T, Nomura T, Morishita A, Yoneyama H, Masaki T. Diabetes mellitus and metformin in hepatocellular carcinoma. World journal of gastroenterology. 2016; 22:6100-6113
53. Qu Z, Zhang Y, Liao M, Chen Y, Zhao J, Pan Y. In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma. Hepatology research. 2012; 42:922-933
54. Miyoshi H, Kato K, Iwama H, Maeda E, Sakamoto T, Fujita K, Toyota Y, Tani J, Nomura T, Mimura S, Kobayashi M, Morishita A, Kobara H, et al. Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. International journal of oncology. 2014; 45:322-332
55. Cheng J, Huang T, Li Y, Guo Y, Zhu Y, Wang Q, Tan X, Chen W, Zhang Y, Cheng W, Yamamoto T, Jing X, Huang J. AMP-activated protein kinase suppresses the in vitro and in vivo proliferation of hepatocellular carcinoma. PloS one. 2014; 9:e93256
56. Miyoshi H, Kato K, Iwama H, Maeda E, Sakamoto T, Fujita K, Toyota Y, Tani J, Nomura T, Mimura S, Kobayashi M, Morishita A, Kobara H, Mori H, Yoneyama H, Deguchi A, et al. Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. International journal of oncology. 2014; 45:322-32
57. Kim EH, Kim MS, Cho CK, Jung WG, Jeong YK, Jeong JH. Low and high linear energy transfer radiation sensitization of HCC cells by metformin. Journal of radiation research. 2014; 55:432-442
58. Harris K, Smith L. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. The Annals of pharmacotherapy. 2013; 47:1348-1352
59. Cai X, Hu X, Cai B, Wang Q, Li Y, Tan X, Hu H, Chen X, Huang J, Cheng J, Jing X. Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo. Oncology reports. 2013; 30:2449-2457
60. Kim JH, Alam MM, Park DB, Cho M, Lee SH, Jeon YJ, Yu DY, Kim TD, Kim HY, Cho CG, Lee DH. The Effect of Metformin Treatment on CRBP-I Level and Cancer Development in the Liver of HBx Transgenic Mice. The Korean journal of physiology & pharmacology. 2013; 17:455-461
61. Wang JM, Tseng JT, Chang WC. Induction of human NFIL6beta by epidermal growth factor is mediated through the p38 signaling pathway and cAMP response element-binding protein activation in A431 cells. Molecular biology of the cell. 2005; 16:3365-3376
62. Wang JM, Ko CY, Chen LC, Wang WL, Chang WC. Functional role of NF-IL6beta and its sumoylation and acetylation modifications in promoter activation of cyclooxygenase 2 gene. Nucleic acids research. 2006; 34:217-231
63. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. The EMBO journal. 2000; 19:5720-5728